Independent predictors of NASH and significant fibrosis
| NASH | Significant fibrosis | |||
|---|---|---|---|---|
| OR (95% CI) | p Value | OR (95% CI) | p Value | |
| Model 1 (cohort origin, age, sex, BMI, high blood pressure, triglycerides, total cholesterol and HDL cholesterol levels, HbA1c, ALT, AST and GGT+a single drug among statins, metformin, sulfonylureas or insulin) | ||||
| Statin use | 0.61 (0.35 to 1.07) | 0.086 | 0.52 (0.29 to 0.93) | 0.026 |
| Metformin use | 1.24 (0.68 to 2.27) | 0.476 | 1.06 (0.58 to 1.96) | 0.841 |
| Sulfonylureas use | 0.78 (0.44 to 1.36) | 0.377 | 1.73 (0.98 to 3.05) | 0.061 |
| Insulin use | 2.15 (1.08 to 4.28) | 0.029 | 1.26 (0.65 to 2.42) | 0.493 |
| Model 2 (cohort origin, age, sex, BMI, high blood pressure, triglycerides, total cholesterol and HDL cholesterol levels, HbA1c, ALT, AST and GGT+number of antidiabetic drugs and a single drug among statins, metformin, sulfonylureas or insulin) | ||||
| Statin use | 0.57 (0.32 to 1.01) | 0.055 | 0.46 (0.26 to 0.83) | 0.010 |
| Metformin use | 1.00 (0.47 to 2.12) | 0.997 | 0.58 (0.27 to 1.26) | 0.170 |
| Sulfonylureas use | 0.55 (0.28 to 1.07) | 0.076 | 1.34 (0.69 to 2.62) | 0.392 |
| Insulin use | 2.03 (0.98 to 4.17) | 0.055 | 1.01 (0.51 to 2.01) | 0.978 |
| Model 3 (cohort origin, age, sex, BMI, high blood pressure, triglycerides, total cholesterol and HDL cholesterol levels, HbA1c, ALT, AST and GGT+statins, metformin, sulfonylureas and insulin at the same time) | ||||
| Statin use | 0.57 (0.32 to 1.01) | 0.055 | 0.47 (0.26 to 0.84) | 0.011 |
| Metformin use | 1.38 (0.74 to 2.56) | 0.315 | 1.00 (0.53 to 1.89) | 0.992 |
| Sulfonylureas use | 0.87 (0.48 to 1.56) | 0.632 | 2.04 (1.11 to 3.74) | 0.022 |
| Insulin use | 2.24 (1.11 to 4.54) | 0.025 | 1.58 (0.79 to 3.14) | 0.196 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, γ glutamyl transpeptidase; HbA1c, glycated haemoglobin.